• In April 2026, Indivior Pharmaceuticals raised its full-year net revenue and adjusted EBITDA guidance after strong first-quarter results driven by expanded uptake of its long-acting opioid use disorder treatment SUBLOCADE, and announced a US$175,000,000 accelerated share repurchase to be completed by the end of June 2026.
• This combination of stronger operating performance and a shift in capital allocation toward share buybacks highlights management’s increasing focus on profitability and direct shareholder returns.
• Now we’ll examine how the upgraded full-year guidance and accelerated share repurchase reshape Indivior’s existing investment narrative.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Indivior Pharmaceuticals Investment Narrative Recap

To own Indivior today, you need to believe SUBLOCADE can keep scaling within long acting injectable treatment for opioid use disorder while the company converts that growth into durable earnings and cash flow. The upgraded 2026 revenue and EBITDA guidance reinforces SUBLOCADE’s role as the key near term catalyst, while the main risk remains the company’s heavy reliance on this single franchise. The April guidance raise appears to strengthen, rather than materially change, that near term setup.

The most relevant recent announcement is the US$175,000,000 accelerated share repurchase slated for completion by the end of June 2026. Alongside higher guidance, this move underscores Indivior’s focus on turning SUBLOCADE driven operating momentum into per share earnings growth and capital returns, which could amplify the impact of any upside or downside in SUBLOCADE adoption on shareholder outcomes over the next few years.

Yet against this improving story, investors should still pay close attention to how dependent Indivior remains on SUBLOCADE volumes and U.S. policy trends...

Indivior Pharmaceuticals' narrative projects $1.2 billion revenue and $477.5 million earnings by 2028. This requires 1.7% yearly revenue growth and a roughly $353 million earnings increase from $124.0 million today.

Uncover how Indivior Pharmaceuticals' forecasts yield a $37.86 fair value, in line with its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming revenue near US$1.3 billion and earnings above US$590 million by 2029, which is far more bullish than consensus and leans heavily on deeper SUBLOCADE penetration, so you should recognize how much views can differ and consider how this guidance upgrade and buyback might reshape both that upside case and the risk that expense cuts could start to cap growth.

Explore 5 other fair value estimates on Indivior Pharmaceuticals - why the stock might be worth over 3x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Indivior Pharmaceuticals research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Indivior Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Indivior Pharmaceuticals' overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.